Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 128 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: punch biopsy Clear all

Conditions: Immune and Microbial Reconstitution, Systemic Viral Infection, Acute-graft-versus-host Disease, Chronic Graft-versus-host-disease, Recurrent Malignancy, Cytokine Release Syndrome, Allogenic Related Donors, Cell Therapy/Immunotherapy Patients
Interventions: Blood Sample, Stool Sample, Urine Sample, Bronchoalveolar Lavage (BAL) fluid, Gastrointestinal biopsy x 2-4, Skin biopsy, Skin, mouth, and/or ocular swab, Apheresis Product, Final cellular product; Diagnostic Test
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Not listed
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Breast Cancer
Interventions: HER-2/neu intracellular domain protein, flow cytometry, immunohistochemistry staining method, biopsy, Sterile water placement; Biological · Other · Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 2
States / cities: Seattle, Washington

Conditions: Wound Bleeding
Interventions: BXP154, Placebo; Drug
Lead sponsor: Bio 54, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: DeLand, Florida

Conditions: Young Onset Parkinson Disease, Parkinson Disease
Interventions: Not listed
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Plaque-type Psoriasis
Interventions: Skin biopsies; Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: New Orleans, Louisiana • East Windsor, New Jersey • Philadelphia, Pennsylvania + 1 more

Conditions: Inflammation
Interventions: Adenosine, Sodium Nitroprusside; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Bilateral Nasolabial Fold Wrinkles
Interventions: Autologous Human Fibroblasts (azficel-T), Placebo; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 6
States / cities: Beverly Hills, California • San Diego, California • Snellville, Georgia + 3 more

Conditions: Retinoblastoma
Interventions: Skin Biopsy, Blood Draw; Other
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Parkinson Disease, Parkinsonism, Dementia With Lewy Bodies, Multiple System Atrophy, Progressive Supranuclear Palsy, Corticobasal Degeneration
Interventions: punch skin biopsy; Procedure
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 21 Years to 89 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Cleveland, Ohio • South Euclid, Ohio

Conditions: Burns
Interventions: ST266; Biological
Lead sponsor: Noveome Biotherapeutics, formerly Stemnion; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 14
States / cities: Mobile, Alabama • Los Angeles, California • Gainesville, Florida + 11 more

Conditions: Psoriatic Arthritis
Interventions: Treatment with Apremilast; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Tick-borne Diseases, Tick Resistance, Lyme Disease
Interventions: Xenodiagnosis Ticks, skin biopsy, blood draw; Device · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Wound Healing
Interventions: TolaSure Topical Gel; Drug
Lead sponsor: BioMendics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Cutaneous T-cell Lymphoma, Sezary Syndrome, Mycosis Fungoides, Eczema, Atopic Dermatitis
Interventions: Blood draw, skin biopsy or urine collection; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2032
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetic Foot Ulcers
Interventions: FGF-1 141; Drug
Lead sponsor: Phage Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Scar, Wound Healing
Interventions: SLI-F06; Drug
Lead sponsor: Scarless Laboratories, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Encinitas, California • Austin, Texas

Conditions: Acne Scarring of the Face
Interventions: Autologous Human Fibroblasts (azficel-T), Placebo; Biological
Lead sponsor: Castle Creek Biosciences, LLC.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 7
States / cities: Beverly Hills, California • San Diego, California • Santa Monica, California + 4 more

Conditions: Vulvar Cancers, Vulva Neoplasm, Vulvar Dysplasia
Interventions: J-Tip, Lidocaine HCl 1%; Device · Drug
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bleeding
Interventions: 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects
Interventions: CC-90001; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Daytona Beach, Florida • Fair Lawn, New Jersey

Conditions: Skin Laxity
Interventions: Profound system; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Myelofibroses
Interventions: Pevonedistat, Ruxolitinib, Peripheral blood draw, Skin biopsy; Drug · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hyper-Immunoglobulin E. Syndrome (HEIS), Chronic Granulomatous Disease (CGD)
Interventions: Blister induction, Skin Biopsies; Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 7 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Renal Cell Carcinoma, Hepatocellular Carcinoma, Colorectal Carcinoma
Interventions: skin punch biopsy; Procedure
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 2
States / cities: Lebanon, New Hampshire • White River Junction, Vermont

Search by objective public record fields.

Monitoring of Immune and Microbial Reconstitution in (HCT) and Novel Immunotherapies

Immune Response in Patients Who Have Undergone Vaccine Therapy for Stage III or Stage IV Breast Cancer That Overexpresses HER2

Treatment of Post-Punch Biopsy Bleeding in Anticoagulated Patients Using Self-Administered BXP154

Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms

Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab

Role of Adenosine in the Release of VEGF and Cytokines

Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles

Feasibility of Generating Pluripotent Stem Cells From Patients With Familial Retinoblastoma

Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism

ST266 Versus Standard Care In Treating Partial Thickness Burns

Treatment With Apremilast in Patients With Psoriatic Arthritis

Human Immune Response to Ixodes Scapularis Tick Bites

Safety and Efficacy of Topical TolaSure on Skin Punch Biopsies in Healthy Participants

Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

Safety Study of Topical Human FGF-1 for Wound Healing

Dose Regimen Study of SLI-F06 in Healthy Volunteers

Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

Needlefree Lidocaine Application for Vulvar Biopsies

A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Radio Frequency Microneedling for Suprapatellar Skin

Pevonedistat in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis

Skin Immunity Sample Collection Involving Blisters and Biopsies

Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in Human Skin